RSV Burden in Hong Kong

NCT07321314 | Not Yet Recruiting

• 1 other identifier: RSV burden
• Study Type: observational
• Target: 10,000
• Locations: 1 country
• Sites: 1

Brief Summary

RSV infection causes significant mortality and morbidity in susceptible adults. There are many publications on the global RSV disease burden in infants and young children but data on adults are lacking with lots of knowledge gaps. Currently there is no established effective antiviral therapy for RSV. RSV vaccines have recently become available commercially but the Center for Health Protection (Hong Kong) has yet to discuss procurement of RSV vaccines for the high risk groups. Thus a prospective study to assess the disease burden of RSV infection in adults would be of great interest.

Conditions

RSV

Outcome Measures

Primary Outcomes (1)

• Incidence of RSV infection

  The incidence of RSV infection based on the RSV detection rate in respiratory specimens collected from patients with respiratory tract infection symptoms

  1 month

Secondary Outcomes (1)

• Incidence of severe RSV infection

  1 month

Study Arms (2)

RSV group

Patients with respiratory tract infection symptom and RSV confirmed in clinical specimens

Diagnostic Test: Serial specimen sampling

Control group

Patients with respiratory tract infection symptom but no RSV confirmed in clinical specimens

Interventions

Serial specimen sampling DIAGNOSTIC_TEST

Serial sampling of nasopharyngeal swab, saliva and sputum for RSV on day 3, 5, 7, 14, 28 (during hospitalization) for patients confirmed with RSV infection. Blood taking will be arranged on day 28 for serology purpose

RSV group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients hospitalized for community-acquired respiratory tract infection symptoms

You may qualify if:

• Community-acquired respiratory tract infection symptoms
• Age \>= 18

You may not qualify if:

• Unable to provide a good quality of sputum and saliva

Sponsors & Collaborators

• Chinese University of Hong Kong: lead

Study Sites (1)

Chinese University of Hong Kong

Hong Kong, Hong Kong

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Nasopharyngeal aspirate / swab, saliva, sputum, blood

Study Officials

• David SC Hui, MD

  Chinese University of Hong Kong

  STUDY DIRECTOR

Central Study Contacts

Ka Pang Chan, MBChB

CONTACT

+852 35052211; chankapang@cuhk.edu.hk

Karen Yiu

CONTACT

+852 35053532; ysyiu@cuhk.edu.hk

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Month
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: December 22, 2025
• First Posted: January 7, 2026
• Study Start: March 1, 2026
• Primary Completion (Estimated): February 29, 2028
• Study Completion (Estimated): August 31, 2028
• Last Updated: January 8, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

HK (1)